Bal Pharma Limited

BSE: 524824 NSE: BALPHARMA
Bal Pharma Limited - pharma in Bangalore South, Karnataka, India. FY 2026 financials and compliance.
CIN L85110KA1987PLC008368 Incorporated 19 May 1987 ROC Bangalore HQ Bangalore South, Karnataka, India
Active Listed - NSE: BALPHARMA · BSE: 524824 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹311.66 Cr
▲ 2.83% YoY
EBITDA · FY 2026
₹33.83 Cr
▲ 6.52% YoY
Net profit · FY 2026
₹6.32 Cr
▼ 12.22% YoY
Authorised capital
₹24.5 Cr
Registered with MCA
Paid-up capital
₹15.92 Cr
Issued & subscribed
Open charges
₹234.84 Cr
Satisfied ₹198.12 Cr
Company age
39 yrs
Est. 1987
Employees · EPFO
715
Latest available

About Bal Pharma Limited

Data last updated: 09 January 2026

Bal Pharma Limited is a public limited company based in Bangalore South, Karnataka, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 19 May 1987, the company has been in operation for over 39 years.

Registered with ROC Bangalore under CIN L85110KA1987PLC008368. Listed on BSE: 524824 and NSE: BALPHARMA.

Capital: an authorised share capital of ₹24.5 Cr and a paid-up capital of ₹15.92 Cr. It is led by directors including Ravindrakumar Kothari and Himesh Virupakshaya.

Last AGM: 25 September 2025. Financial statements filed for year ended 31 March 2025. Office: Bangalore South, Karnataka.

As per the financials filed for FY 2025, the company reported a revenue of ₹305.29 Cr, a decline of 11% compared to the previous year.

The company has a workforce of approximately 715 employees as per the latest available data. Its group structure includes 4 subsidiaries.

The company is associated with 1 brand - Bal Pharma. As per MCA filings, the company has open charges of ₹234.84 Cr and satisfied charges of ₹198.12 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website balpharma.com.

Company Details of Bal Pharma Limited
CIN L85110KA1987PLC008368
Registration Number 008368
Incorporation Date 19 May 1987
ROC Bangalore
Listing Status Listed (BSE: 524824, NSE: BALPHARMA)
Company Status Active
Date of Last AGM 25 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Shailesh Dheerajmal Siroya Managing Director Ravindrakumar Kothari Director Himesh Virupakshaya Deputy Nodal Officer
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    balpharma.com
  • Social Media
  • Registered Address
    21 – 22 Bommasandra, Industrial Area, Bangalore South, Karnataka, India – 560099
  • Industry
    Pharma, API Manufacturers
Company report
Bal Pharma Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Bal Pharma Limited report

Financials, compliance, directors, charges, ownership and filings for Bal Pharma Limited in one report.

10-year financials Directors & ownership Charges & compliance

Associated Brands with Bal Pharma Limited

Bal Pharma Limited operates one associated brand: Bal Pharma. These brands represent Bal Pharma Limited's diversified market presence and brand portfolio.

Brand Description Website
Bal Pharma
Manufacturer of pharmaceutical APIs, formulations, and Ayurvedic products balpharma.com

Business Activity of Bal Pharma Limited

Bal Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Bal Pharma Limited

Bal Pharma Limited is audited by SSJNB & CO (ICAI peer reviewed, certificate valid till 2029-03-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
SSJNB & CO (ICAI peer reviewed, certificate valid till 2029-03-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Bal Pharma Limited

Bal Pharma Limited is currently managed by 9 directors, with 24 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Ravindrakumar Kothari
Also directs: Balance Clinics Llp, Lifezen Healthcare Private Limited, Aurum Research & Analytical Solutions Private Limited and 1 more
Director 05 May 2025 1 Years 2 Months Current
Himesh Virupakshaya Deputy Nodal Officer 19 Jan 2023 3 Years 5 Months Current
Shailesh Dheerajmal Siroya
Also directs: Balance Clinics Llp, Lifezen Healthcare Private Limited, Kaunshya Investments Private Limited and 2 more
Managing Director 01 Aug 2004 21 Years 11 Months Current
Nicola Neeladri
Also directs: Umiya Buildcon Limited, Isg Novasoft Technologies Limited, Bluetech Design Private Limited
Director 23 May 2020 6 Years 1 Months Current
Jatish Sheth
Also directs: Meganza Pharma Llp, Srushti Pharmaceuticals Private Limited
Director 28 Dec 2020 5 Years 6 Months Current
Bheekamchand Mukesh Additional Director 13 Nov 2025 0 Years 7 Months Current
Showing 6 of 9 current directors. View all directors

Financials of Bal Pharma Limited FY 2026 filings available

Bal Pharma Limited reported revenue of ₹311.66 Cr (up 2.83% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹311.66 Cr ▲ 2.83%
Profit · FY 2026
₹6.32 Cr ▼ 12.22%
EBITDA · FY 2026
₹33.83 Cr ▲ 6.52%
Revenue₹ Cr · Consolidated0200400FY 2020: ₹171 Cr171FY 2020FY 2021: ₹251 Cr · +46.4% YoY251+46.4%FY 2021FY 2022: ₹281 Cr · +12.2% YoY281+12.2%FY 2022FY 2023: ₹304 Cr · +8.2% YoY304+8.2%FY 2023FY 2024: ₹339 Cr · +11.5% YoY339+11.5%FY 2024FY 2025: ₹303 Cr · -10.7% YoY303-10.7%FY 2025FY 2026: ₹312 Cr · +2.8% YoY312+2.8%FY 2026
Net Profit₹ Cr · Consolidated-15-10-50510FY 2020: ₹13 Cr (loss)-12.9FY 2020FY 2021: ₹5 Cr · +136.6% YoY4.7+136.6%FY 2021FY 2022: ₹6 Cr · +21.1% YoY5.7+21.1%FY 2022FY 2023: ₹3 Cr · -54.1% YoY2.6-54.1%FY 2023FY 2024: ₹7 Cr · +184.3% YoY7.4+184.3%FY 2024FY 2025: ₹7 Cr · -3.3% YoY7.2-3.3%FY 2025FY 2026: ₹6 Cr · -12.2% YoY6.3-12.2%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year050100Q1'25: ₹74 Cr · +5.6% YoY74.4+5.6%Q1'25Q2'25: ₹74 Cr · -20.4% YoY73.7-20.4%Q2'25Q3'25: ₹73 Cr · -10.4% YoY73.2-10.4%Q3'25Q4'25: ₹82 Cr · -13.5% YoY81.9-13.5%Q4'25Q1'26: ₹66 Cr · -11.4% YoY65.9-11.4%Q1'26Q2'26: ₹74 Cr · +0.4% YoY74+0.4%Q2'26Q3'26: ₹88 Cr · +19.9% YoY87.7+19.9%Q3'26Q4'26: ₹84 Cr · +2.7% YoY84.1+2.7%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹311.66 Cr ₹303.08 Cr ₹339.22 Cr ₹304.22 Cr ₹281.21 Cr ₹250.53 Cr ₹171.09 Cr
Other Income ₹1.93 Cr ₹2.2 Cr ₹2.85 Cr ₹94.06 Lakh ₹5.15 Cr ₹1.14 Cr ₹1.84 Cr
Total Income ₹313.59 Cr ₹305.29 Cr ₹342.07 Cr ₹305.16 Cr ₹286.37 Cr ₹251.67 Cr ₹172.93 Cr
Cost of Materials Consumed ₹160.97 Cr ₹149.89 Cr ₹181.58 Cr ₹179.19 Cr ₹163.99 Cr ₹135.47 Cr ₹72.2 Cr
Purchases of Stock-in-Trade ₹9.23 Cr ₹15.06 Cr ₹11.24 Cr ₹11.45 Cr ₹8.43 Cr ₹10.43 Cr ₹8.54 Cr
Changes in Inventories -₹12.23 Cr -₹7.05 Cr -₹1.06 Cr -₹17.87 Cr -₹4.89 Cr ₹5.05 Cr ₹3.38 Cr
Employee Benefit Expense ₹66.46 Cr ₹62.4 Cr ₹60.38 Cr ₹55.3 Cr ₹47.25 Cr ₹41.88 Cr ₹50.43 Cr
Finance Costs ₹16.82 Cr ₹16.85 Cr ₹15.26 Cr ₹12.19 Cr ₹10.41 Cr ₹11.97 Cr ₹12.45 Cr
Depreciation & Amortisation ₹11.08 Cr ₹9.77 Cr ₹10.07 Cr ₹9.13 Cr ₹9.04 Cr ₹9.52 Cr ₹7.68 Cr
Other Expenses ₹55.33 Cr ₹53.23 Cr ₹55.56 Cr ₹51.03 Cr ₹42.96 Cr ₹33.25 Cr ₹31.78 Cr
Total Expenses ₹307.65 Cr ₹300.15 Cr ₹333.02 Cr ₹300.41 Cr ₹277.18 Cr ₹247.56 Cr ₹186.46 Cr
Profit Before Exceptional Items & Tax ₹5.94 Cr ₹5.14 Cr ₹9.05 Cr ₹4.75 Cr ₹9.18 Cr ₹4.1 Cr -₹13.53 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹5.94 Cr ₹5.14 Cr ₹9.05 Cr ₹4.75 Cr ₹9.18 Cr ₹4.1 Cr -₹13.53 Cr
Total Tax Expense -₹38.62 Lakh -₹2.1 Cr ₹1.6 Cr ₹2.13 Cr ₹3.48 Cr -₹60.96 Lakh -₹63.76 Lakh
Net Profit ₹6.32 Cr ₹7.2 Cr ₹7.45 Cr ₹2.62 Cr ₹5.7 Cr ₹4.71 Cr -₹12.89 Cr
  attributable to Owners ₹6.28 Cr ₹7.22 Cr ₹7.39 Cr ₹0 ₹5.61 Cr ₹4.74 Cr ₹0
  attributable to NCI ₹3.65 Lakh ₹2.13 Lakh ₹5.35 Lakh ₹0 ₹9.34 Lakh -₹3.02 Lakh ₹0
Other Comprehensive Income ₹43.85 Lakh ₹0 ₹36.08 Lakh ₹0 ₹31,000 ₹20.42 Lakh -₹29.02 Lakh
Total Comprehensive Income ₹6.76 Cr ₹7.2 Cr ₹7.81 Cr ₹2.62 Cr ₹5.71 Cr ₹4.92 Cr -₹13.18 Cr
EBITDA (computed) ₹33.83 Cr ₹31.76 Cr ₹34.38 Cr ₹26.06 Cr ₹28.63 Cr ₹25.6 Cr ₹6.6 Cr
Basic EPS ₹3.95 ₹4.56 ₹4.94 ₹1.67 ₹3.79 ₹3.34 ₹-8.62
Diluted EPS ₹3.95 ₹4.56 ₹4.96 ₹1.68 ₹3.71 ₹3.34 ₹-8.62
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹375.54 Cr ₹335.69 Cr ₹320.39 Cr ₹313.17 Cr
Non-current Assets ₹113.31 Cr ₹100.82 Cr ₹85.38 Cr ₹85.02 Cr
Current Assets ₹262.23 Cr ₹234.87 Cr ₹235.01 Cr ₹228.16 Cr
Property, Plant & Equipment ₹76.75 Cr ₹70.99 Cr ₹61.61 Cr ₹62.18 Cr
Inventories ₹116.36 Cr ₹103.02 Cr ₹87.81 Cr ₹98.01 Cr
Trade Receivables ₹93.63 Cr ₹92.44 Cr ₹99.62 Cr ₹93.98 Cr
Cash & Equivalents ₹2.3 Cr ₹1.75 Cr ₹4.2 Cr ₹1.49 Cr
Equity (Net Worth) ₹82.25 Cr ₹77.4 Cr ₹69.26 Cr ₹63.7 Cr
Equity Share Capital ₹15.92 Cr ₹15.92 Cr ₹15.8 Cr ₹15.69 Cr
Borrowings (Non-current) ₹31.88 Cr ₹31.41 Cr ₹36.38 Cr ₹30.52 Cr
Borrowings (Current) ₹127.63 Cr ₹119 Cr ₹103.27 Cr ₹100.48 Cr
Total Debt (computed) ₹159.52 Cr ₹150.41 Cr ₹139.65 Cr ₹131 Cr
Current Liabilities ₹249.23 Cr ₹219.5 Cr ₹203.91 Cr ₹209.33 Cr
Total Liabilities ₹293.29 Cr ₹258.29 Cr ₹251.13 Cr ₹249.47 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹7.87 Cr ₹20.74 Cr ₹329.19 Cr ₹23.02 Cr ₹32.05 Cr
Investing Cash Flow -₹9.85 Cr -₹18.13 Cr ₹0 ₹18.43 Cr ₹11.34 Cr
Financing Cash Flow -₹27.32 Cr ₹29.24 Lakh ₹34.58 Cr ₹0 ₹1.11 Cr
Capital Expenditure ₹0 ₹0 ₹0 ₹0 ₹0
Free Cash Flow (computed) ₹7.87 Cr ₹20.74 Cr ₹329.19 Cr ₹23.02 Cr ₹32.05 Cr
Dividends Paid ₹1.95 Lakh ₹0 ₹0 ₹0 ₹0
Net Change in Cash -₹29.31 Cr ₹2.9 Cr ₹363.78 Cr ₹41.45 Cr ₹44.5 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹84.08 Cr ₹87.69 Cr ₹74.02 Cr ₹65.87 Cr ₹81.88 Cr ₹73.15 Cr ₹73.69 Cr ₹74.36 Cr ₹94.63 Cr ₹81.66 Cr ₹92.54 Cr ₹70.39 Cr
Other Income -₹23.65 Lakh ₹32.62 Lakh ₹1.12 Cr ₹72.22 Lakh ₹1.08 Cr ₹50.64 Lakh -₹20.49 Lakh ₹81.84 Lakh ₹2.45 Cr ₹9.53 Lakh ₹14.21 Lakh ₹15.67 Lakh
Total Income ₹83.84 Cr ₹88.02 Cr ₹75.14 Cr ₹66.59 Cr ₹82.96 Cr ₹73.66 Cr ₹73.49 Cr ₹75.18 Cr ₹97.08 Cr ₹81.76 Cr ₹92.68 Cr ₹70.54 Cr
Cost of Materials Consumed ₹41.14 Cr ₹43.51 Cr ₹40.29 Cr ₹36.03 Cr ₹38.7 Cr ₹37.58 Cr ₹37.29 Cr ₹36.31 Cr ₹51.9 Cr ₹37.91 Cr ₹50.22 Cr ₹41.55 Cr
Purchases of Stock-in-Trade ₹1.42 Cr ₹2.04 Cr ₹1.78 Cr ₹3.98 Cr ₹6.97 Cr ₹3.54 Cr ₹1.4 Cr ₹3.14 Cr ₹4.75 Cr ₹1.72 Cr ₹3.26 Cr ₹1.52 Cr
Changes in Inventories -₹4.23 Cr ₹60.63 Lakh -₹2.14 Cr -₹6.47 Cr -₹1.7 Cr -₹4.27 Cr -₹70.34 Lakh -₹37.53 Lakh -₹2.88 Cr ₹6.22 Cr -₹16.11 Lakh -₹4.24 Cr
Employee Benefit Expense ₹18.07 Cr ₹17.32 Cr ₹16.27 Cr ₹14.8 Cr ₹15.49 Cr ₹15.98 Cr ₹16.02 Cr ₹14.91 Cr ₹15.64 Cr ₹15.26 Cr ₹15.3 Cr ₹14.19 Cr
Finance Costs ₹4.06 Cr ₹4.85 Cr ₹3.86 Cr ₹4.05 Cr ₹3.95 Cr ₹5.01 Cr ₹3.65 Cr ₹4.24 Cr ₹4.14 Cr ₹3.66 Cr ₹3.82 Cr ₹3.64 Cr
Depreciation & Amortisation ₹3.06 Cr ₹3.23 Cr ₹2.27 Cr ₹2.52 Cr ₹2.18 Cr ₹2.69 Cr ₹2.48 Cr ₹2.43 Cr ₹2.16 Cr ₹2.96 Cr ₹2.42 Cr ₹2.53 Cr
Other Expenses ₹17.12 Cr ₹14.66 Cr ₹12.09 Cr ₹11.46 Cr ₹14.77 Cr ₹12.57 Cr ₹11.98 Cr ₹13.91 Cr ₹15.63 Cr ₹12.76 Cr ₹16.23 Cr ₹10.93 Cr
Total Expenses ₹80.62 Cr ₹86.23 Cr ₹74.42 Cr ₹66.38 Cr ₹80.37 Cr ₹73.09 Cr ₹72.13 Cr ₹74.56 Cr ₹91.33 Cr ₹80.49 Cr ₹91.09 Cr ₹70.11 Cr
Profit Before Exceptional Items & Tax ₹3.22 Cr ₹1.79 Cr ₹71.73 Lakh ₹20.85 Lakh ₹2.59 Cr ₹56.63 Lakh ₹1.36 Cr ₹61.75 Lakh ₹5.75 Cr ₹1.27 Cr ₹1.6 Cr ₹43.06 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹3.22 Cr ₹1.79 Cr ₹71.73 Lakh ₹20.85 Lakh ₹2.59 Cr ₹56.63 Lakh ₹1.36 Cr ₹61.75 Lakh ₹5.75 Cr ₹1.27 Cr ₹1.6 Cr ₹43.06 Lakh
Total Tax Expense -₹38.62 Lakh ₹0 ₹0 ₹0 -₹2.83 Cr ₹4.84 Lakh ₹31.94 Lakh ₹35.8 Lakh ₹21.89 Lakh ₹41.69 Lakh ₹62.99 Lakh ₹33.59 Lakh
Net Profit ₹3.6 Cr ₹1.79 Cr ₹71.73 Lakh ₹20.85 Lakh ₹5.38 Cr ₹51.79 Lakh ₹1.04 Cr ₹25.95 Lakh ₹5.53 Cr ₹84.92 Lakh ₹96.94 Lakh ₹9.47 Lakh
  attributable to Owners ₹3.59 Cr ₹1.78 Cr ₹70.95 Lakh - ₹6.73 Cr ₹48.12 Lakh ₹1.04 Cr ₹25.91 Lakh ₹5.47 Cr ₹88.89 Lakh ₹94.57 Lakh ₹8.43 Lakh
  attributable to NCI ₹1.02 Lakh ₹1.07 Lakh ₹77,000 - -₹1.53 Lakh ₹3.67 Lakh ₹11,000 ₹3,000 ₹5.91 Lakh -₹3.97 Lakh ₹2.37 Lakh ₹1.05 Lakh
Other Comprehensive Income ₹43.85 Lakh ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹36.08 Lakh ₹0 ₹0 ₹0
Total Comprehensive Income ₹4.04 Cr ₹1.79 Cr ₹71.73 Lakh ₹20.85 Lakh ₹5.38 Cr ₹51.79 Lakh ₹1.04 Cr ₹25.95 Lakh ₹5.89 Cr ₹84.92 Lakh ₹96.94 Lakh ₹9.47 Lakh
EBITDA (computed) ₹10.33 Cr ₹9.87 Cr ₹6.85 Cr ₹6.78 Cr ₹8.72 Cr ₹8.26 Cr ₹7.49 Cr ₹7.28 Cr ₹12.05 Cr ₹7.89 Cr ₹7.84 Cr ₹6.6 Cr
Basic EPS ₹2.26 ₹1.12 ₹0.45 ₹0.13 ₹3.40 ₹0.33 ₹0.65 ₹0.16 ₹3.73 ₹0.54 ₹0.62 ₹0.06
Diluted EPS ₹2.26 ₹1.12 ₹0.45 ₹0.13 ₹3.40 ₹0.33 ₹0.65 ₹0.16 ₹3.74 ₹0.54 ₹0.62 ₹0.06
Latest 12 quarters shown of 24 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹310.8 Cr ₹302.5 Cr ₹338.54 Cr ₹303.1 Cr ₹280.37 Cr ₹249.31 Cr ₹170.67 Cr
Other Income ₹2 Cr ₹2.15 Cr ₹3.35 Cr ₹2.15 Cr ₹6.49 Cr ₹2.7 Cr ₹3.62 Cr
Total Income ₹312.8 Cr ₹304.65 Cr ₹341.89 Cr ₹305.25 Cr ₹286.86 Cr ₹252.01 Cr ₹174.29 Cr
Cost of Materials Consumed ₹160.97 Cr ₹149.89 Cr ₹181.57 Cr ₹176.45 Cr ₹162.95 Cr ₹135.47 Cr ₹79.44 Cr
Purchases of Stock-in-Trade ₹9.13 Cr ₹14.97 Cr ₹11.23 Cr ₹11.39 Cr ₹8.4 Cr ₹9.98 Cr ₹8.7 Cr
Changes in Inventories -₹12.25 Cr -₹7.08 Cr -₹1.06 Cr -₹17.9 Cr -₹4.85 Cr ₹5.13 Cr -₹3.43 Cr
Employee Benefit Expense ₹65.92 Cr ₹61.83 Cr ₹56.11 Cr ₹51.91 Cr ₹44.46 Cr ₹39.62 Cr ₹48.77 Cr
Finance Costs ₹16.81 Cr ₹16.85 Cr ₹15.24 Cr ₹12.16 Cr ₹10.4 Cr ₹11.96 Cr ₹12.42 Cr
Depreciation & Amortisation ₹11.06 Cr ₹9.65 Cr ₹8.45 Cr ₹7.48 Cr ₹7.24 Cr ₹7.26 Cr ₹7.03 Cr
Other Expenses ₹54.79 Cr ₹52.82 Cr ₹58.25 Cr ₹55.22 Cr ₹46.21 Cr ₹32.79 Cr ₹30.93 Cr
Total Expenses ₹306.43 Cr ₹298.91 Cr ₹329.79 Cr ₹296.7 Cr ₹274.8 Cr ₹242.2 Cr ₹183.86 Cr
Profit Before Exceptional Items & Tax ₹6.37 Cr ₹5.73 Cr ₹12.11 Cr ₹8.55 Cr ₹12.06 Cr ₹9.8 Cr -₹9.57 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹6.37 Cr ₹5.73 Cr ₹12.11 Cr ₹8.55 Cr ₹12.06 Cr ₹9.8 Cr -₹9.57 Cr
Total Tax Expense -₹38.61 Lakh -₹2.07 Cr ₹1.83 Cr ₹2.42 Cr ₹3.48 Cr ₹69.93 Lakh -₹4.17 Lakh
Net Profit ₹6.75 Cr ₹7.8 Cr ₹10.27 Cr ₹6.13 Cr ₹8.57 Cr ₹9.1 Cr -₹9.53 Cr
  attributable to Owners - - - - - - ₹0
  attributable to NCI - - - - - - ₹0
Other Comprehensive Income ₹43.38 Lakh -₹4.32 Lakh ₹35.37 Lakh ₹22.63 Lakh -₹60,000 ₹8.85 Lakh -₹30.42 Lakh
Total Comprehensive Income ₹7.19 Cr ₹7.76 Cr ₹10.63 Cr ₹6.35 Cr ₹8.57 Cr ₹9.19 Cr -₹9.83 Cr
EBITDA (computed) ₹34.23 Cr ₹32.23 Cr ₹35.79 Cr ₹28.19 Cr ₹29.69 Cr ₹29.02 Cr ₹9.87 Cr
Basic EPS ₹4.27 ₹4.89 ₹6.72 ₹3.90 ₹5.79 ₹6.41 ₹-6.72
Diluted EPS ₹4.27 ₹4.89 ₹6.75 ₹3.94 ₹5.67 ₹6.41 ₹-6.72
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹391.06 Cr ₹350.56 Cr ₹361.3 Cr ₹347.7 Cr
Non-current Assets ₹115.42 Cr ₹102.91 Cr ₹80.16 Cr ₹77.75 Cr
Current Assets ₹275.64 Cr ₹247.65 Cr ₹281.14 Cr ₹269.95 Cr
Property, Plant & Equipment ₹76.73 Cr ₹70.95 Cr ₹53.18 Cr ₹52.62 Cr
Inventories ₹116.13 Cr ₹102.78 Cr ₹87.49 Cr ₹97.69 Cr
Trade Receivables ₹96.36 Cr ₹94.85 Cr ₹103.1 Cr ₹94.84 Cr
Cash & Equivalents ₹2.19 Cr ₹1.64 Cr ₹4.04 Cr ₹1.23 Cr
Equity (Net Worth) ₹104.1 Cr ₹98.82 Cr ₹105.58 Cr ₹96.03 Cr
Equity Share Capital ₹15.92 Cr ₹15.92 Cr ₹15.8 Cr ₹15.69 Cr
Borrowings (Non-current) ₹31.88 Cr ₹31.4 Cr ₹36.35 Cr ₹30.52 Cr
Borrowings (Current) ₹121.86 Cr ₹113.21 Cr ₹97.48 Cr ₹94.71 Cr
Total Debt (computed) ₹153.75 Cr ₹144.61 Cr ₹133.83 Cr ₹125.23 Cr
Current Liabilities ₹243.3 Cr ₹213.46 Cr ₹209.16 Cr ₹212.15 Cr
Total Liabilities ₹286.96 Cr ₹251.74 Cr ₹255.72 Cr ₹251.67 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹8.82 Cr ₹20.31 Cr ₹33.35 Cr -₹8.5 Cr ₹18.42 Cr
Investing Cash Flow -₹26.82 Cr -₹14.9 Cr ₹2.57 Cr -₹17.95 Cr ₹30.76 Cr
Financing Cash Flow -₹11.76 Cr -₹7.83 Cr ₹24.21 Cr ₹0 ₹0
Capital Expenditure ₹0 ₹18.77 Cr -₹10.5 Cr ₹0 ₹0
Free Cash Flow (computed) ₹8.82 Cr ₹1.54 Cr ₹22.85 Cr -₹8.5 Cr ₹18.42 Cr
Dividends Paid ₹0 ₹1.91 Cr ₹1.57 Cr ₹0 ₹0
Net Change in Cash -₹28.45 Cr -₹2.42 Cr ₹60.13 Cr -₹26.45 Cr ₹49.18 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹83.92 Cr ₹87.49 Cr ₹73.75 Cr ₹65.64 Cr ₹81.78 Cr ₹72.89 Cr ₹74.7 Cr ₹73.13 Cr ₹94.58 Cr ₹81.49 Cr ₹92.3 Cr ₹70.17 Cr
Other Income -₹21.82 Lakh ₹34.51 Lakh ₹1.13 Cr ₹74.11 Lakh ₹99.1 Lakh ₹81.97 Lakh ₹35.5 Lakh ₹81.48 Lakh ₹2.23 Cr ₹25.71 Lakh ₹41.31 Lakh ₹44.75 Lakh
Total Income ₹83.7 Cr ₹87.84 Cr ₹74.88 Cr ₹66.38 Cr ₹82.77 Cr ₹73.7 Cr ₹75.06 Cr ₹73.94 Cr ₹96.81 Cr ₹81.75 Cr ₹92.71 Cr ₹70.61 Cr
Cost of Materials Consumed ₹41.14 Cr ₹43.51 Cr ₹40.29 Cr ₹36.03 Cr ₹39.92 Cr ₹37.55 Cr ₹36.13 Cr ₹36.31 Cr ₹51.89 Cr ₹37.92 Cr ₹50.19 Cr ₹41.57 Cr
Purchases of Stock-in-Trade ₹1.44 Cr ₹2.01 Cr ₹1.7 Cr ₹3.97 Cr ₹5.67 Cr ₹3.5 Cr ₹2.83 Cr ₹2.98 Cr ₹4.76 Cr ₹1.67 Cr ₹3.38 Cr ₹1.42 Cr
Changes in Inventories -₹4.19 Cr ₹61.31 Lakh -₹2.14 Cr -₹6.52 Cr -₹1.64 Cr -₹4.36 Cr -₹73.81 Lakh -₹34.32 Lakh -₹2.89 Cr ₹6.27 Cr -₹24.52 Lakh -₹4.2 Cr
Employee Benefit Expense ₹17.92 Cr ₹17.19 Cr ₹16.15 Cr ₹14.67 Cr ₹15.35 Cr ₹14.81 Cr ₹14.88 Cr ₹13.84 Cr ₹14.56 Cr ₹14.17 Cr ₹14.18 Cr ₹13.2 Cr
Finance Costs ₹4.05 Cr ₹4.85 Cr ₹3.86 Cr ₹4.05 Cr ₹3.94 Cr ₹5.01 Cr ₹4.18 Cr ₹3.71 Cr ₹4.12 Cr ₹3.66 Cr ₹3.82 Cr ₹3.64 Cr
Depreciation & Amortisation ₹3.04 Cr ₹3.23 Cr ₹2.27 Cr ₹2.52 Cr ₹2.07 Cr ₹2.33 Cr ₹2.12 Cr ₹2.08 Cr ₹1.76 Cr ₹2.55 Cr ₹2.02 Cr ₹2.12 Cr
Other Expenses ₹16.99 Cr ₹14.49 Cr ₹11.98 Cr ₹11.33 Cr ₹14.66 Cr ₹13.66 Cr ₹14.12 Cr ₹13.27 Cr ₹15.94 Cr ₹13.84 Cr ₹17.14 Cr ₹11.34 Cr
Total Expenses ₹80.39 Cr ₹85.89 Cr ₹74.1 Cr ₹66.05 Cr ₹79.96 Cr ₹72.5 Cr ₹73.52 Cr ₹71.84 Cr ₹90.14 Cr ₹80.08 Cr ₹90.48 Cr ₹69.08 Cr
Profit Before Exceptional Items & Tax ₹3.31 Cr ₹1.95 Cr ₹78.15 Lakh ₹32.33 Lakh ₹2.81 Cr ₹1.2 Cr ₹1.53 Cr ₹2.11 Cr ₹6.67 Cr ₹1.67 Cr ₹2.23 Cr ₹1.53 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹3.31 Cr ₹1.95 Cr ₹78.15 Lakh ₹32.33 Lakh ₹2.81 Cr ₹1.2 Cr ₹1.53 Cr ₹2.11 Cr ₹6.67 Cr ₹1.67 Cr ₹2.23 Cr ₹1.53 Cr
Total Tax Expense -₹38.61 Lakh ₹0 ₹0 ₹0 -₹2.79 Cr ₹4.84 Lakh ₹31.94 Lakh ₹35.8 Lakh ₹45.08 Lakh ₹41.69 Lakh ₹62.99 Lakh ₹33.59 Lakh
Net Profit ₹3.7 Cr ₹1.95 Cr ₹78.15 Lakh ₹32.33 Lakh ₹5.61 Cr ₹1.16 Cr ₹1.21 Cr ₹1.75 Cr ₹6.22 Cr ₹1.26 Cr ₹1.6 Cr ₹1.2 Cr
Other Comprehensive Income ₹43.38 Lakh ₹0 ₹0 ₹0 -₹4.32 Lakh ₹0 ₹0 ₹0 ₹35.37 Lakh ₹0 ₹0 ₹0
Total Comprehensive Income ₹4.13 Cr ₹1.95 Cr ₹78.15 Lakh ₹32.33 Lakh ₹5.56 Cr ₹1.16 Cr ₹1.21 Cr ₹1.75 Cr ₹6.57 Cr ₹1.26 Cr ₹1.6 Cr ₹1.2 Cr
EBITDA (computed) ₹10.41 Cr ₹10.02 Cr ₹6.91 Cr ₹6.89 Cr ₹8.82 Cr ₹8.55 Cr ₹7.83 Cr ₹7.89 Cr ₹12.55 Cr ₹7.89 Cr ₹8.07 Cr ₹7.29 Cr
Basic EPS ₹2.60 ₹1.22 ₹0.49 ₹0.20 ₹3.51 ₹0.73 ₹0.76 ₹1.11 ₹4.16 ₹0.80 ₹1.02 ₹0.76
Diluted EPS ₹2.60 ₹1.22 ₹0.49 ₹0.20 ₹3.51 ₹0.73 ₹0.76 ₹1.11 ₹4.18 ₹0.80 ₹1.02 ₹0.76
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Bal Pharma Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Bal Pharma Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 50.86%, foreign institutional investors hold 0.14%, retail and other public shareholders hold 49.01% of Bal Pharma Limited. The company had 15,214 shareholders on record.

Promoters: 50.86%FII (Foreign Institutional): 0.14%Retail & Others: 49.01%
Mar 2026
QUARTER
50.86% Promoters
0.14% FII (Foreign Institutional)
49.01% Retail & Others
Promoter holding - history
Now 50.86% · Mar 2026High 52.00% · Apr 2022Low 42.45% · Sep 2018
41%44%47%50%53%Dec 2015Jun 2018Dec 2020Mar 2023Sep 2025Dec 2015: 48.83%Mar 2016: 48.83%Jun 2016: 44.35%Sep 2016: 44.35%Dec 2016: 44.35%Mar 2017: 44.35%Jun 2017: 44.44%Sep 2017: 44.57%Dec 2017: 44.57%Mar 2018: 44.57%Jun 2018: 44.57%Sep 2018: 42.45%Dec 2018: 42.45%Mar 2019: 42.45%Jun 2019: 42.45%Sep 2019: 42.45%Dec 2019: 42.45%Mar 2020: 42.45%Jun 2020: 42.45%Sep 2020: 42.45%Dec 2020: 42.45%Mar 2021: 44.98%Jun 2021: 44.84%Sep 2021: 46.87%Dec 2021: 49.57%Mar 2022: 49.57%Apr 2022: 52.00%Jun 2022: 52.00%Sep 2022: 52.00%Dec 2022: 51.61%Mar 2023: 51.61%Jun 2023: 51.61%Sep 2023: 51.61%Dec 2023: 51.23%Mar 2024: 51.23%Jun 2024: 51.23%Sep 2024: 50.86%Dec 2024: 50.86%Mar 2025: 50.86%Jun 2025: 50.86%Sep 2025: 50.86%Dec 2025: 50.86%Mar 2026: 50.86%52.00%42.45%50.86%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters50.86%50.86%50.86%50.86%50.86%50.86%
Public49.14%49.14%49.14%49.14%49.14%49.14%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters50.86%50.86%51.23%51.61%49.57%44.98%42.45%42.45%44.57%44.35%48.83%
Public49.14%49.14%48.77%48.39%50.43%55.02%57.55%57.55%55.43%55.65%51.17%
Promoter change (YoY, %pts)+0.00-0.37-0.38+2.04+4.59+2.53+0.00-2.12+0.22-4.48-

Board & Governance of Bal Pharma Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Bal Pharma Limited has 6 directors - 3 independent and 2 executive. The board is chaired by SHAILESH SIROYA.

DirectorPositionOn board sinceListed boards
SHAILESH SIROYA Executive Director · MD · Chairperson 1994-07-15 1
HIMESH VIRUPAKSHYA Executive Director 2019-09-28 1
RAVINDRA KUMAR KOTHARI Non-Executive - Non Independent Director 2025-05-05 1
JATISH SHETH Non-Executive - Independent Director 2020-12-28 1
MUKESH BHEEKAMCHAND Non-Executive - Independent Director 2025-11-13 1
NICOLA NEELADI Non-Executive - Independent Director 2020-05-23 2
Board Committees
CommitteeMembers
Audit Committee JATISH SHETH (Chairperson), MUKESH BHEEKAMCHAND, NICOLA NEELADI
Nomination and remuneration committee JATISH SHETH (Chairperson), MUKESH BHEEKAMCHAND, NICOLA NEELADI, RAVINDRA KUMAR KOTHARI
Stakeholders Relationship Committee JATISH SHETH (Chairperson), MUKESH BHEEKAMCHAND, NICOLA NEELADI, RAVINDRA KUMAR KOTHARI, SHAILESH SIROYA

Group Structure of Bal Pharma Limited

Bal Pharma Limited has 4 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Bal Pharma Limited's business expansion strategy and organizational complexity.

4
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Lifezen Healthcare Private Limited U24230KA2014PTC077114 -
Golden Drugs Private Limited U24232KA2012PTC157474 -
Aurum Research & Analytical Solutions Private Limited U72100KA2023PTC177577 -
Bal Research Foundation U73100KA2014NPL076995 -

Showing major subsidiaries. Total: 4.

Charges & Borrowings of Bal Pharma Limited

Open charges
₹234.84 Cr
Satisfied charges
₹198.12 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹106.58 Cr
Others₹64.83 Cr
Canara Bank₹58.78 Cr
Sidbi₹4.29 Cr
Axis Bank Limited₹0.36 Cr
Latest charge details
DateLenderAmountStatus
20 Nov 2025 Others ₹4.4 Cr Open
13 Nov 2025 Hdfc Bank Limited ₹5 Cr Open
23 Oct 2025 Hdfc Bank Limited ₹24.9 Lakh Open
28 Aug 2025 Others ₹22 Cr Open
22 Aug 2025 Others ₹3 Cr Open

Total charge records: 41 View all charges

Employees and EPFO Compliance at Bal Pharma Limited

Bal Pharma Limited has a workforce of 715 employees as of Mar 31, 2025.

Employee count
715
Active EPFO establishments
2
Employee growth
-12.7%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Bal Pharma Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Bal Pharma Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Bal Pharma Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Bal Pharma Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Bal Pharma Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Bal Pharma Limited

MSME Payment Delays by Bal Pharma Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Bal Pharma Limited

Subsidiaries & Group Companies of Bal Pharma Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Bal Pharma Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Bal Pharma Limited

MCA Filings & Documents of Bal Pharma Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Bal Pharma Limited

Charges
27 Nov 2025
A charge with Others of Rs. 22.00 Cr registered on 28 Aug 2025 with Charge ID 101169142 was modified on 27 Nov 2025.
Charges
20 Nov 2025
A charge with Others amounted to Rs. 4.40 Cr with Charge ID 101186985 was registered on 20 Nov 2025.
Charges
13 Nov 2025
A charge with Hdfc Bank Limited amounted to Rs. 5.00 Cr with Charge ID 101183756 was registered on 13 Nov 2025.
Directors
13 Nov 2025
Bheekamchand Mukesh was appointed as a Additional Director on 13 Nov 2025 & has been associated with this company since 7 months 26 days.
Charges
23 Oct 2025
A charge with Hdfc Bank Limited amounted to Rs. 0.25 Cr with Charge ID 101180259 was registered on 23 Oct 2025.
Charges
26 Sep 2025
A charge registered on 08 Feb 2024 via Charge ID 100873015 with Others was fully satisfied on 26 Sep 2025.

Recent News on Bal Pharma Limited

Bal Pharma, Australian co venture
06 Mar 2018 · Business Line

Frequently Asked Questions about Bal Pharma Limited

Bal Pharma Limited is an active public limited company in the pharma sector based in Bangalore South, Karnataka, India. It was incorporated on 19 May 1987 (39+ years old) and is registered under CIN L85110KA1987PLC008368. Listed on BSE: 524824 and NSE: BALPHARMA. The company has 715 employees.

Bal Pharma Limited reported revenue of ₹305.29 Cr for FY 2025 (down 11.00% YoY).

The current directors of Bal Pharma Limited are:

The primary industry of Bal Pharma Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Bal Pharma Limited is listed on both BSE (code: 524824) and NSE (symbol: BALPHARMA).

Bal Pharma Limited can be reached at the registered office: 21 – 22 Bommasandra, Industrial Area, Bangalore South, Karnataka, India – 560099, or through the website balpharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available